AMLX NASDAQ
Amylyx Pharmaceuticals, Inc.
1W: -0.9%
1M: -8.1%
3M: +38.6%
YTD: +137.2%
1Y: +89.3%
3Y: +63.7%
$28.00
+0.91 (+3.37%)
Weekly Expected Move ±6.1%
$24
$26
$27
$29
$31
Credit Risk of going bust: lower than 78% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Amylyx Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $3.40B.
Distance to default 9.13 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 75.9%; Altman Z'' 1.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Amylyx Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $3.40B.
Distance to default 9.13 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 75.9%; Altman Z'' 1.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.4B
52W Range10.83-41.14
Volume1,371,103
Avg Volume2,131,813
Beta-0.20
Dividend—
Analyst Ratings
Company Info
CEOJoshua Cohen
Employees136
SectorHealthcare
IndustryBiotechnology
IPO Date2022-01-07
Websiteamylyx.com
55 Cambridge Parkway
Cambridge, MA 02142
US
Cambridge, MA 02142
US
617 682 0917
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Latest News
10 mid-cap healthcare stocks with the strongest momentum grades
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Legal & General Group Plc Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| MILNE GEORGE M JR | S-Sale | 30,000 | $27.70 | 2026-10-05 |
| Mazzariello Gina | S-Sale | 9,525 | $32.46 | 2026-09-10 |
| Mazzariello Gina | S-Sale | 11 | $33.34 | 2026-09-10 |
| Klee Justin B. | S-Sale | 29,025 | $32.13 | 2026-09-10 |
| Klee Justin B. | S-Sale | 1,439 | $33.16 | 2026-09-10 |